Thinly traded micro cap Tyme Technologies (TYME +16.2%) is up on almost an 8x surge in volume on the heels of its collaboration agreement with Eagle Pharmaceuticals (EGRX -1.1%) aimed at promoting lead candidate SM-88 in advanced cancers.
Under the terms of the partnership, Eagle will invest $20M in Tyme via the purchase of 10M restricted common shares at $2/share. Tyme will receive a $20M milestone upon the successful completion of the first of three events: (1) achievement of the primary endpoint of overall survival in its TYME-88-Panc pivotal trial, (2) achievement of the primary endpoint of overall survival in the PanCAN Precision Promise℠ SM-88 registration arm or (3) FDA approval of SM-88 in any cancer.
The parties have agreed to co-promote SM-88 in the U.S. with Eagle responsible for 25% of the sales effort for which it will receive 15% of net revenue. Tyme will be responsible for the remaining 75% of the promotional effort (and 85% of U.S. sales) in addition to clinical development, regulatory approval, commercial strategy, marketing, reimbursement and manufacturing. It retains the right to repurchase Eagle's co-promotion right for $200M.
According to Tyme, SM-88 is a combination therapy that uses a proprietary dysfunctional tyrosine derivative to interrupt the metabolic processes of cancer cells, breaking down their defenses and making them vulnerable to oxidative stress and death.
Try Seeking Alpha PREMIUM for unlimited analysis on TYME